This idea is supported by findings from a genome-wide association study that found that a functional haplotype in the human NFE2L2 promoter that results in increased transcriptional activity of the NRF2 was associated with decreased risk and delayed onset of PD [18]. This evidence concerns the gene NFE2L2 and Parkinson disease.